nach oben

Medical Oncology

Erschienen in:

01.08.2014 | Original Paper

Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients

verfasst von: Majed S. Alokail, Nasser M. Al-Daghri, Abdul Khader Mohammed, Paul Vanhoutte, Amal Alenad

Erschienen in: Medical Oncology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Obesity has been associated with increased incidence and mortality of breast cancer. The precise relation between obesity and breast cancer is yet to be determined, with few studies linking them with altered serum levels adipokines and inflammatory cytokines. The relevance of the expression of genes encoding for adipokines and inflammatory cytokines in the peripheral blood and their contribution to obesity and breast cancer has not been fully investigated. We aim to identify potential transcriptional biomarkers in blood samples that may assist to underpin the link between obesity and breast cancer. Therefore, have investigated whether or not the expression levels, of selected genes [tumor necrosis factor-α (TNFα), interleukin 6 (IL-6), adiponectin, leptin, C-reactive protein (CRP), parathyroid hormone (PTH), tumor protein 53 (TP53) and erythroblastic leukemia viral oncogene 2 (ErbB2)] were altered in blood samples of lean, overweight/obese and breast cancer subjects. Blood samples were obtained from 37 lean, 19 overweight/obese and 12 breast cancer patients. Real-time polymerase chain reaction assays were performed to detect TNFα, IL-6, adiponectin, leptin, CRP, PTH, TP53 and ErbB2 gene transcripts. Transcript levels of TNFα were significantly higher by 1.4-fold and 2.1-fold in blood cells of overweight/obese and breast cancer patients, respectively, compared with lean control subjects. Transcript levels of IL-6 were significantly higher by 2.3-fold in blood cells from breast cancer patients compared with lean control subjects with normal body mass index, and no significant difference was found in the expression level of IL-6 transcripts between overweight/obese and lean control subjects. The ErbB2 transcript levels were significantly higher by 4.72-fold compared to lean control subjects and were also significantly higher compared to overweight/obese subjects. Breast cancer and obesity are associated with altered mRNA levels of cytokines and tumor marker in peripheral blood.

Loureiro ML, Nayga RM. International dimensions of obesity and overweight related problems: an economics perspective. Am J Agric Econ. 2005;87(5):1147–53.CrossRef

Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, et al. Obesity in Saudi Arabia. Saudi Med J. 2005;26(5):824–9.PubMed

Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52(8):2097–101.PubMedCrossRef

Festa A, D’Agostino R Jr, Williams K, Karter A, Mayer-Davis E, Tracy R, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2001;25(10):1407.CrossRef

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745–51.PubMed

Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85(9):3338–42.PubMed

Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA J Am Med Assoc. 2003;289(14):1799–804.CrossRef

Bruun JM, Verdich C, Toubro S, Astrup A, Richelsen B. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol. 2003;148(5):535–42.PubMedCrossRef

Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation. 2004;110(12):1564–71.PubMedCrossRef

10.

DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clinicians. 2011;61:408.CrossRef

11.

El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5(4):225–33.PubMedCrossRef

12.

Harvie M, Howell A. Energy balance adiposity and breast cancer–energy restriction strategies for breast cancer prevention. Obes Rev. 2006;7(1):33–47.PubMedCrossRef

13.

Lithgow D, Covington C. Chronic inflammation and breast pathology: a theoretical model. Biol Res Nurs. 2005;7(2):118–29.PubMedCrossRef

14.

Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine. 2005;26(1):19–24.PubMedCrossRef

15.

Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007;92(4):1510–6.PubMedCrossRef

16.

Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007;61(9):824–33.PubMedCentralPubMedCrossRef

17.

Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk—a prospective nested case–control study. Int J Cancer. 2010;127(9):2159–68.PubMedCrossRef

18.

Slamon DJGW, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.PubMedCrossRef

19.

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253(5015):49–53.PubMedCrossRef

20.

Burczynski ME, Dorner AJ. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics. 2006;7(2):187–202.PubMedCrossRef

21.

Friedwald W, Levy R, Frederickson D. Estimation of plasma low density lipoprotein cholesterol concentration with use of preparative ultracentrifugation. Clin Chem. 1972;18:499–509.

22.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta] [Delta] CT method. Methods. 2001;25(4):402–8.PubMedCrossRef

23.

Albuquerque K, Price M, Badley R, Jonrup I, Pearson D, Blamey R, et al. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol. 1995;21(5):504–9.PubMedCrossRef

24.

Zhang G, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999;19(2B):1427.PubMed

25.

Bozcuk H, Uslu G, Samur M, YIldIz M, Özben T, Özdogan M, et al. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 2004;27(2–3):58–65.CrossRef

26.

Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, et al. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm (Lond). 2012;9:48.CrossRef

27.

Alokail MS, Al-Daghri NM, Al-Attas OS, Hussain T. Combined effects of obesity and type 2 diabetes contribute to increased breast cancer risk in premenopausal women. Cardiovasc Diabetol. 2009;8(1):33.PubMedCentralPubMedCrossRef

28.

Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res. 2011;71(8):2988–99.PubMedCrossRef

29.

Sánchez J, Priego T, Picó C, Ahrens W, De Henauw S, Fraterman A, et al. Blood cells as a source of transcriptional biomarkers of childhood obesity and its related metabolic alterations: results of the IDEFICS study. J Clin Endocrinol Metab. 2012;97:E648.PubMedCrossRef

30.

O’Rourke R, Kay T, Lyle E, Traxler S, Deveney C, Jobe B, et al. Alterations in peripheral blood lymphocyte cytokine expression in obesity. Clin Exp Immunol. 2006;146(1):39–46.PubMedCentralPubMedCrossRef

31.

Purohit A, Newman S, Reed M. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002;4(2):65–9.PubMedCentralPubMedCrossRef

32.

Berclaz G, Li S, Price K, Coates A, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the international breast cancer study group experience. Ann Oncol. 2004;15(6):875–84.PubMedCrossRef

33.

Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, et al. Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. J Cancer. 2012;3:310.PubMedCentralPubMedCrossRef

34.

de Mello VDF, Kolehmainen M, Schwab U, Mager U, Laaksonen DE, Pulkkinen L, et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism. 2008;57(2):192–9.PubMedCrossRef

35.

Sullivan NJ. Interleukin-6 as a potential mediator of breast cancer progression and non-melanoma skin carcinogenesis. Columbus: Ohio State University; 2009.

36.

Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988–4002.PubMedCentralPubMedCrossRef

37.

Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J. 2007;21(13):3763–70.PubMedCrossRef

38.

Tsiotra P, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res. 2007;39(10):758–63.PubMedCrossRef

39.

Kempf K, Haltern G, Futh R, Herder C, Muller-Scholze S, Gulker H, et al. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction. Horm Metab Res. 2006;38(5):346.PubMedCrossRef

40.

Swiatoniowski G, Dabrowska M, Kłaniewski T, Molenda W. Erb-2 overexpression in breast cancer]. Ginekol Pol. 2003;74(4):332.PubMed

41.

Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2):124–34.PubMedCrossRef

Titel: Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients
verfasst von: Majed S. Alokail
Nasser M. Al-Daghri
Abdul Khader Mohammed
Paul Vanhoutte
Amal Alenad
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 8/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-014-0038-0

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Biomarkers in prostate cancer: new era and prospective

Overexpression of interleukin-8 receptor 2 (IL-8R2) indicates better prognosis in esophageal adenocarcinoma and squamous cell carcinoma procession

Gene expression profiling of peripheral blood cells: new insights into Ewing sarcoma biology and clinical applications

Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI

M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma

The effect of immune microenvironment on the progression and prognosis of colorectal cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie